Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 7 versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 7 versus EPANOVA.
AMINOSYN-PF 7% vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth in parenteral nutrition.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion; typical adult dose: 1-2 g amino acids/kg/day (e.g., 14-28 mL/kg/day for 7% solution) as part of parenteral nutrition. Infusion rate not to exceed 0.1 g amino acids/kg/hour.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
As a mixture of amino acids, individual amino acids have half-lives ranging from minutes to hours; clinically, continuous infusion maintains steady state.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids are primarily cleared by metabolism; less than 10% is excreted unchanged in urine.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution